Characterization of BRCA1 and BRCA2 splicing variants: A collaborative report by ENIGMA consortium members

Mads Thomassen, Ana Blanco, Marco Montagna, Thomas V O Hansen, Inge S. Pedersen, Sara Gutiérrez-Enríquez, Mireia Menéndez, Laura Fachal, Marta Santamariña, Ane Y. Steffensen, Lars Jønson, Simona Agata, Phillip Whiley, Silvia Tognazzo, Eva Tornero, Uffe B. Jensen, Judith Balmaña, Torben A. Kruse, David E. Goldgar, Conxi LázaroOrland Diez, Amanda B. Spurdle, Ana Vega

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Mutations in BRCA1 and BRCA2 predispose carriers to early onset breast and ovarian cancer. A common problem in clinical genetic testing is interpretation of variants with unknown clinical significance. The Evidencebased Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium was initiated to evaluate and implement strategies to characterize the clinical significance of BRCA1 and BRCA2 variants. As an initial project of the ENIGMA Splicing Working Group, we report splicing and multifactorial likelihood analysis of 25 BRCA1 and BRCA2 variants from seven different laboratories. Splicing analysis was performed by reverse transcriptase PCR or mini gene assay, and sequencing to identify aberrant transcripts. The findings were compared to bioinformatic predictions using four programs. The posterior probability of pathogenicity was estimated using multifactorial likelihood analysis, including co-occurrence with a deleterious mutation, segregation and/or report of family history. Abnormal splicing patterns expected to lead to a non-functional protein were observed for 7 variants (BRCA1 c.441+2T>A, c.4184-4185+2del, c.4357+1G >A, c.4987-2A>G, c.5074G>C, BRCA2 c.316+5G>A, and c.8754+3G>C). Combined interpretation of splicing and multifactorial analysis classified an initiation codon variant (BRCA2 c.3G>A) as likely pathogenic, uncertain clinical significance for 7 variants, and indicated low clinical significance or unlikely pathogenicity for another 10 variants. Bioinformatic tools predicted disruption of consensus donor or acceptor sites with high sensitivity, but cryptic site usage was predicted with low specificity, supporting the value of RNA-based assays. The findings also provide further evidence that clinical RNA-based assays should be extended from analysis of invariant dinucleotides to routinely include all variants located within the donor and acceptor consensus splicing sites. Importantly, this study demonstrates the added value of collaboration between laboratories, and across disciplines, to collate and interpret information from clinical testing laboratories to consolidate patient management.

Original languageEnglish
Pages (from-to)1009-1023
Number of pages15
JournalBreast Cancer Research and Treatment
Volume132
Issue number3
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Alleles
Computational Biology
Virulence
Consensus
Tissue Donors
RNA
Mutation
Initiator Codon
Genetic Testing
Reverse Transcriptase Polymerase Chain Reaction
Ovarian Neoplasms
Breast Neoplasms
Genes
Proteins

Keywords

  • BRCA1
  • BRCA2
  • ENIGMA
  • Multifactorial analysis
  • Splice mutations
  • Splicing
  • Splicing sites

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Thomassen, M., Blanco, A., Montagna, M., Hansen, T. V. O., Pedersen, I. S., Gutiérrez-Enríquez, S., ... Vega, A. (2012). Characterization of BRCA1 and BRCA2 splicing variants: A collaborative report by ENIGMA consortium members. Breast Cancer Research and Treatment, 132(3), 1009-1023. https://doi.org/10.1007/s10549-011-1674-0

Characterization of BRCA1 and BRCA2 splicing variants : A collaborative report by ENIGMA consortium members. / Thomassen, Mads; Blanco, Ana; Montagna, Marco; Hansen, Thomas V O; Pedersen, Inge S.; Gutiérrez-Enríquez, Sara; Menéndez, Mireia; Fachal, Laura; Santamariña, Marta; Steffensen, Ane Y.; Jønson, Lars; Agata, Simona; Whiley, Phillip; Tognazzo, Silvia; Tornero, Eva; Jensen, Uffe B.; Balmaña, Judith; Kruse, Torben A.; Goldgar, David E.; Lázaro, Conxi; Diez, Orland; Spurdle, Amanda B.; Vega, Ana.

In: Breast Cancer Research and Treatment, Vol. 132, No. 3, 04.2012, p. 1009-1023.

Research output: Contribution to journalArticle

Thomassen, M, Blanco, A, Montagna, M, Hansen, TVO, Pedersen, IS, Gutiérrez-Enríquez, S, Menéndez, M, Fachal, L, Santamariña, M, Steffensen, AY, Jønson, L, Agata, S, Whiley, P, Tognazzo, S, Tornero, E, Jensen, UB, Balmaña, J, Kruse, TA, Goldgar, DE, Lázaro, C, Diez, O, Spurdle, AB & Vega, A 2012, 'Characterization of BRCA1 and BRCA2 splicing variants: A collaborative report by ENIGMA consortium members', Breast Cancer Research and Treatment, vol. 132, no. 3, pp. 1009-1023. https://doi.org/10.1007/s10549-011-1674-0
Thomassen, Mads ; Blanco, Ana ; Montagna, Marco ; Hansen, Thomas V O ; Pedersen, Inge S. ; Gutiérrez-Enríquez, Sara ; Menéndez, Mireia ; Fachal, Laura ; Santamariña, Marta ; Steffensen, Ane Y. ; Jønson, Lars ; Agata, Simona ; Whiley, Phillip ; Tognazzo, Silvia ; Tornero, Eva ; Jensen, Uffe B. ; Balmaña, Judith ; Kruse, Torben A. ; Goldgar, David E. ; Lázaro, Conxi ; Diez, Orland ; Spurdle, Amanda B. ; Vega, Ana. / Characterization of BRCA1 and BRCA2 splicing variants : A collaborative report by ENIGMA consortium members. In: Breast Cancer Research and Treatment. 2012 ; Vol. 132, No. 3. pp. 1009-1023.
@article{e2fe12e82b4f43fc86684a0c39ec0668,
title = "Characterization of BRCA1 and BRCA2 splicing variants: A collaborative report by ENIGMA consortium members",
abstract = "Mutations in BRCA1 and BRCA2 predispose carriers to early onset breast and ovarian cancer. A common problem in clinical genetic testing is interpretation of variants with unknown clinical significance. The Evidencebased Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium was initiated to evaluate and implement strategies to characterize the clinical significance of BRCA1 and BRCA2 variants. As an initial project of the ENIGMA Splicing Working Group, we report splicing and multifactorial likelihood analysis of 25 BRCA1 and BRCA2 variants from seven different laboratories. Splicing analysis was performed by reverse transcriptase PCR or mini gene assay, and sequencing to identify aberrant transcripts. The findings were compared to bioinformatic predictions using four programs. The posterior probability of pathogenicity was estimated using multifactorial likelihood analysis, including co-occurrence with a deleterious mutation, segregation and/or report of family history. Abnormal splicing patterns expected to lead to a non-functional protein were observed for 7 variants (BRCA1 c.441+2T>A, c.4184-4185+2del, c.4357+1G >A, c.4987-2A>G, c.5074G>C, BRCA2 c.316+5G>A, and c.8754+3G>C). Combined interpretation of splicing and multifactorial analysis classified an initiation codon variant (BRCA2 c.3G>A) as likely pathogenic, uncertain clinical significance for 7 variants, and indicated low clinical significance or unlikely pathogenicity for another 10 variants. Bioinformatic tools predicted disruption of consensus donor or acceptor sites with high sensitivity, but cryptic site usage was predicted with low specificity, supporting the value of RNA-based assays. The findings also provide further evidence that clinical RNA-based assays should be extended from analysis of invariant dinucleotides to routinely include all variants located within the donor and acceptor consensus splicing sites. Importantly, this study demonstrates the added value of collaboration between laboratories, and across disciplines, to collate and interpret information from clinical testing laboratories to consolidate patient management.",
keywords = "BRCA1, BRCA2, ENIGMA, Multifactorial analysis, Splice mutations, Splicing, Splicing sites",
author = "Mads Thomassen and Ana Blanco and Marco Montagna and Hansen, {Thomas V O} and Pedersen, {Inge S.} and Sara Guti{\'e}rrez-Enr{\'i}quez and Mireia Men{\'e}ndez and Laura Fachal and Marta Santamari{\~n}a and Steffensen, {Ane Y.} and Lars J{\o}nson and Simona Agata and Phillip Whiley and Silvia Tognazzo and Eva Tornero and Jensen, {Uffe B.} and Judith Balma{\~n}a and Kruse, {Torben A.} and Goldgar, {David E.} and Conxi L{\'a}zaro and Orland Diez and Spurdle, {Amanda B.} and Ana Vega",
year = "2012",
month = "4",
doi = "10.1007/s10549-011-1674-0",
language = "English",
volume = "132",
pages = "1009--1023",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Characterization of BRCA1 and BRCA2 splicing variants

T2 - A collaborative report by ENIGMA consortium members

AU - Thomassen, Mads

AU - Blanco, Ana

AU - Montagna, Marco

AU - Hansen, Thomas V O

AU - Pedersen, Inge S.

AU - Gutiérrez-Enríquez, Sara

AU - Menéndez, Mireia

AU - Fachal, Laura

AU - Santamariña, Marta

AU - Steffensen, Ane Y.

AU - Jønson, Lars

AU - Agata, Simona

AU - Whiley, Phillip

AU - Tognazzo, Silvia

AU - Tornero, Eva

AU - Jensen, Uffe B.

AU - Balmaña, Judith

AU - Kruse, Torben A.

AU - Goldgar, David E.

AU - Lázaro, Conxi

AU - Diez, Orland

AU - Spurdle, Amanda B.

AU - Vega, Ana

PY - 2012/4

Y1 - 2012/4

N2 - Mutations in BRCA1 and BRCA2 predispose carriers to early onset breast and ovarian cancer. A common problem in clinical genetic testing is interpretation of variants with unknown clinical significance. The Evidencebased Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium was initiated to evaluate and implement strategies to characterize the clinical significance of BRCA1 and BRCA2 variants. As an initial project of the ENIGMA Splicing Working Group, we report splicing and multifactorial likelihood analysis of 25 BRCA1 and BRCA2 variants from seven different laboratories. Splicing analysis was performed by reverse transcriptase PCR or mini gene assay, and sequencing to identify aberrant transcripts. The findings were compared to bioinformatic predictions using four programs. The posterior probability of pathogenicity was estimated using multifactorial likelihood analysis, including co-occurrence with a deleterious mutation, segregation and/or report of family history. Abnormal splicing patterns expected to lead to a non-functional protein were observed for 7 variants (BRCA1 c.441+2T>A, c.4184-4185+2del, c.4357+1G >A, c.4987-2A>G, c.5074G>C, BRCA2 c.316+5G>A, and c.8754+3G>C). Combined interpretation of splicing and multifactorial analysis classified an initiation codon variant (BRCA2 c.3G>A) as likely pathogenic, uncertain clinical significance for 7 variants, and indicated low clinical significance or unlikely pathogenicity for another 10 variants. Bioinformatic tools predicted disruption of consensus donor or acceptor sites with high sensitivity, but cryptic site usage was predicted with low specificity, supporting the value of RNA-based assays. The findings also provide further evidence that clinical RNA-based assays should be extended from analysis of invariant dinucleotides to routinely include all variants located within the donor and acceptor consensus splicing sites. Importantly, this study demonstrates the added value of collaboration between laboratories, and across disciplines, to collate and interpret information from clinical testing laboratories to consolidate patient management.

AB - Mutations in BRCA1 and BRCA2 predispose carriers to early onset breast and ovarian cancer. A common problem in clinical genetic testing is interpretation of variants with unknown clinical significance. The Evidencebased Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium was initiated to evaluate and implement strategies to characterize the clinical significance of BRCA1 and BRCA2 variants. As an initial project of the ENIGMA Splicing Working Group, we report splicing and multifactorial likelihood analysis of 25 BRCA1 and BRCA2 variants from seven different laboratories. Splicing analysis was performed by reverse transcriptase PCR or mini gene assay, and sequencing to identify aberrant transcripts. The findings were compared to bioinformatic predictions using four programs. The posterior probability of pathogenicity was estimated using multifactorial likelihood analysis, including co-occurrence with a deleterious mutation, segregation and/or report of family history. Abnormal splicing patterns expected to lead to a non-functional protein were observed for 7 variants (BRCA1 c.441+2T>A, c.4184-4185+2del, c.4357+1G >A, c.4987-2A>G, c.5074G>C, BRCA2 c.316+5G>A, and c.8754+3G>C). Combined interpretation of splicing and multifactorial analysis classified an initiation codon variant (BRCA2 c.3G>A) as likely pathogenic, uncertain clinical significance for 7 variants, and indicated low clinical significance or unlikely pathogenicity for another 10 variants. Bioinformatic tools predicted disruption of consensus donor or acceptor sites with high sensitivity, but cryptic site usage was predicted with low specificity, supporting the value of RNA-based assays. The findings also provide further evidence that clinical RNA-based assays should be extended from analysis of invariant dinucleotides to routinely include all variants located within the donor and acceptor consensus splicing sites. Importantly, this study demonstrates the added value of collaboration between laboratories, and across disciplines, to collate and interpret information from clinical testing laboratories to consolidate patient management.

KW - BRCA1

KW - BRCA2

KW - ENIGMA

KW - Multifactorial analysis

KW - Splice mutations

KW - Splicing

KW - Splicing sites

UR - http://www.scopus.com/inward/record.url?scp=84863868894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863868894&partnerID=8YFLogxK

U2 - 10.1007/s10549-011-1674-0

DO - 10.1007/s10549-011-1674-0

M3 - Article

C2 - 21769658

AN - SCOPUS:84863868894

VL - 132

SP - 1009

EP - 1023

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -